Sensus Healthcare, Inc.SRTS
Price (close)
$2.91
Market cap
$47.9M
P/E
—
Revenue (TTM)
$17.5M
Net income
-$15.5M
Dividend yield
—
1-year total return
-7.0%
Net margin
-88.5%
Revenue growth
-53.4%
Debt / equity
—
What Sensus Healthcare, Inc. does.
its subsidiaries, Sensus Medical Devices Ltd. and Sensus Healthcare Services, LLC, unless the context otherwise indicates, “Sensus,”
highly effective, non-invasive treatments for non-melanoma skin cancer (NMSC) and post-surgical keloid scar prevention. The Company
of dedicated research and development, and has successfully incorporated SRT into a portfolio of treatment devices: the SRT-100 TM ,
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $9.6M | $27.0M | $44.5M | $24.4M | $41.8M | $27.5M |
| Net income | -$6.8M | $4.1M | $24.2M | $485,000 | $6.6M | -$7.7M |
| Free cash flow | -$793,000 | -$414,000 | -$1.6M | -$2.4M | -$1.1M | $332,000 |
More on SRTS.
- Sensus Healthcare, Inc. summary
- Sensus Healthcare, Inc. financial statements
- Sensus Healthcare, Inc. key metrics
- Sensus Healthcare, Inc. health scores and style box
- Sensus Healthcare, Inc. earnings
- Sensus Healthcare, Inc. dividends
- Sensus Healthcare, Inc. valuation
- Sensus Healthcare, Inc. ownership and insiders
- Sensus Healthcare, Inc. peers
Figures from Sensus Healthcare, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.